[go: up one dir, main page]

MX385203B - Compuestos y métodos para tratar infecciones bacterianas. - Google Patents

Compuestos y métodos para tratar infecciones bacterianas.

Info

Publication number
MX385203B
MX385203B MX2019013291A MX2019013291A MX385203B MX 385203 B MX385203 B MX 385203B MX 2019013291 A MX2019013291 A MX 2019013291A MX 2019013291 A MX2019013291 A MX 2019013291A MX 385203 B MX385203 B MX 385203B
Authority
MX
Mexico
Prior art keywords
compounds
methods
sup
bacterial infections
treating bacterial
Prior art date
Application number
MX2019013291A
Other languages
English (en)
Other versions
MX2019013291A (es
Inventor
- VEGA Camilo VELEZ
Jan Romero
- PREVOIR Janelle COMITA
Jing Zhang
Mark Sylvester
Ruben Tommasi
Satenig Guler
- REVILLE Thomas Francois DURAND
Xiaoyun Wu
Original Assignee
Entasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entasis Therapeutics Inc filed Critical Entasis Therapeutics Inc
Publication of MX2019013291A publication Critical patent/MX2019013291A/es
Publication of MX385203B publication Critical patent/MX385203B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En la presente se proporcionan compuestos antibacterianos representados por la Formula I,(I); o una sal farmaceuticamente aceptable del mismo, en donde X, Y, R4, R5 y R6 son como se definen en la presente. Tambien se proporcionan composiciones farmaceuticas que comprenden los compuestos de Formula I.
MX2019013291A 2017-05-08 2018-05-08 Compuestos y métodos para tratar infecciones bacterianas. MX385203B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762502867P 2017-05-08 2017-05-08
PCT/US2018/031593 WO2018208769A1 (en) 2017-05-08 2018-05-08 Compounds and methods for treating bacterial infections

Publications (2)

Publication Number Publication Date
MX2019013291A MX2019013291A (es) 2020-01-15
MX385203B true MX385203B (es) 2025-03-14

Family

ID=62223332

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013291A MX385203B (es) 2017-05-08 2018-05-08 Compuestos y métodos para tratar infecciones bacterianas.

Country Status (27)

Country Link
US (1) US11046694B2 (es)
EP (1) EP3630111B1 (es)
JP (1) JP7058322B2 (es)
KR (1) KR102611447B1 (es)
CN (1) CN110709081B (es)
AU (1) AU2018266640B2 (es)
CY (1) CY1125340T1 (es)
DK (1) DK3630111T3 (es)
EA (1) EA038393B1 (es)
ES (1) ES2907858T3 (es)
HR (1) HRP20220231T1 (es)
HU (1) HUE057592T2 (es)
IL (1) IL270380B (es)
LT (1) LT3630111T (es)
MA (1) MA48743A (es)
MX (1) MX385203B (es)
MY (1) MY201377A (es)
NZ (1) NZ758200A (es)
PE (1) PE20200333A1 (es)
PH (1) PH12019502509A1 (es)
PL (1) PL3630111T3 (es)
PT (1) PT3630111T (es)
SG (1) SG11201909443YA (es)
SI (1) SI3630111T1 (es)
SM (1) SMT202200110T1 (es)
TW (1) TWI791018B (es)
WO (1) WO2018208769A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
FI3833665T3 (fi) 2018-08-09 2023-10-09 Antabio Sas Diatsabisyklo-oktanoneja seriini-beeta-laktamaasien inhibiittoreina
CN111675641B (zh) * 2020-06-04 2023-09-08 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 单环β-内酰胺类化合物、单环内酰胺类化合物盐及其制备方法
EP4146651A4 (en) 2021-05-07 2024-06-05 Ningxia Academy of Agriculture and Forestry Sciences SULFONYLAMIDINE SUBSTITUTED COMPOUNDS AND THEIR USE AS BETA-LACTAMASE INHIBITORS
US11814385B2 (en) 2021-06-25 2023-11-14 University Of South Florida Small molecule inhibitors targeting Clostridioides difficile sporulation
WO2025064681A1 (en) * 2023-09-19 2025-03-27 Entasis Therapeutics Inc. Compounds and methods for treating bacterial infections

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU699465B2 (en) 1993-12-29 1998-12-03 Pfizer Inc. Diazabicyclic neurokinin antagonists
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2848210B1 (fr) 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US7507727B2 (en) * 2003-04-07 2009-03-24 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs and methods of using thereof
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
AU2009206119C1 (en) 2008-01-18 2016-05-26 Merck Sharp & Dohme Llc Beta-lactamase inhibitors
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP2921559A1 (en) 2008-06-19 2015-09-23 Astra Zeneca Holding France Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2937034B1 (fr) 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
WO2013014497A1 (en) 2011-07-26 2013-01-31 Wockhardt Limited Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
JP5808860B2 (ja) 2011-07-26 2015-11-10 ウォックハート リミテッド スルバクタム及びベータ−ラクタマーゼインヒビターを含む医薬組成物
PL2748165T3 (pl) 2011-08-27 2017-05-31 Wockhardt Limited Pochodne 1,6-diazabicyklo[3,2,1]oktan-7-onu i ich zastosowanie w leczeniu zakażeń bakteryjnych
ES2606059T3 (es) 2011-08-30 2017-03-17 Wockhardt Limited Derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona y su uso en el tratamiento de infecciones bacterianas
WO2013038330A1 (en) 2011-09-13 2013-03-21 Wockhardt Limited Nitrogen containing compounds and their use
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US20150119363A1 (en) 2012-02-15 2015-04-30 Rempex Pharmaceuticals, Inc.. Methods of treating bacterial infections
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US8916709B2 (en) * 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
AU2013237939A1 (en) 2012-03-30 2014-10-30 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
SG11201406120SA (en) 2012-03-30 2014-10-30 Cubist Pharm Inc ISOXAZOLE β-LACTAMASE INHIBITORS
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
MY174523A (en) 2012-05-30 2020-04-23 Meiji Seika Pharma Co Ltd ?-lactamase inhibitor and process for preparing the same
EP3360877B1 (en) 2012-08-25 2021-02-17 Wockhardt Limited 1,6- diazabicyclo [3,2,1]octan- 7- one derivatives and their use in the treatment of bacterial infections
AU2013308128B2 (en) 2012-09-03 2017-11-02 Wockhardt Limited Antibacterial compositions
UA115683C2 (uk) 2013-02-06 2017-12-11 Пфайзер Енті-Інфектівз Аб Комбінована терапія для лікування госпітальної пневмонії
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
MY196240A (en) 2014-11-17 2023-03-24 Entasis Therapeutics Ltd Combination Therapy for Treatment Of Resistant Bacterial Infections
EP3512851B1 (en) 2016-09-16 2022-07-06 Entasis Therapeutics Limited Beta-lactamase inhibitor compounds

Also Published As

Publication number Publication date
EA038393B1 (ru) 2021-08-20
SMT202200110T1 (it) 2022-05-12
MX2019013291A (es) 2020-01-15
LT3630111T (lt) 2022-03-10
KR20200005586A (ko) 2020-01-15
MA48743A (fr) 2020-04-08
AU2018266640A1 (en) 2019-11-07
PE20200333A1 (es) 2020-02-14
CN110709081A (zh) 2020-01-17
DK3630111T3 (en) 2022-03-14
PH12019502509A1 (en) 2020-07-13
CA3059773A1 (en) 2018-11-15
MY201377A (en) 2024-02-21
US20200165251A1 (en) 2020-05-28
US11046694B2 (en) 2021-06-29
ES2907858T3 (es) 2022-04-26
EA201992370A1 (ru) 2020-03-10
SG11201909443YA (en) 2019-11-28
PL3630111T3 (pl) 2022-05-23
IL270380B (en) 2022-06-01
SI3630111T1 (sl) 2022-05-31
KR102611447B1 (ko) 2023-12-06
EP3630111A1 (en) 2020-04-08
WO2018208769A1 (en) 2018-11-15
TWI791018B (zh) 2023-02-01
HUE057592T2 (hu) 2022-05-28
CY1125340T1 (el) 2024-02-16
HRP20220231T1 (hr) 2022-04-29
AU2018266640B2 (en) 2022-03-03
TW201843152A (zh) 2018-12-16
JP7058322B2 (ja) 2022-04-21
PT3630111T (pt) 2022-03-01
BR112019023130A2 (pt) 2020-05-26
JP2020519687A (ja) 2020-07-02
NZ758200A (en) 2025-12-19
CN110709081B (zh) 2023-09-22
EP3630111B1 (en) 2021-11-24

Similar Documents

Publication Publication Date Title
MX385203B (es) Compuestos y métodos para tratar infecciones bacterianas.
EP4252848A3 (en) Oxysterols and methods of use thereof
EP4609866A3 (en) Oxysterols and methods of use thereof
MX390625B (es) Inhibidores selectivos de jak1.
MX2020007265A (es) Derivados de rapamicina.
MX385731B (es) Compuestos de biaril-monobactam y métodos de uso de los mismos para el tratamiento de infecciones bacterianas.
SA520411524B1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
MX384868B (es) Composiciones para tratar atrofia muscular espinal.
MX2020010690A (es) Oxiesteroles y metodos de uso de los mismos.
EA201691766A1 (ru) Органические соединения, являющиеся монобактамами, для лечения бактериальных инфекций
GEAP202215303A (en) Chromane monobactam compounds for the treatment of bacterial infections
MX392270B (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
WO2015024010A3 (en) Substituted hydroxamic acid compounds
MX388175B (es) Compuestos terapéuticos y métodos para utilizarlos
WO2016100578A3 (en) Antimicrobial polymyxins for treatment of bacterial infections
MX376283B (es) Compuestos de imidazopiridazina.
BR112018074985A2 (pt) composições antibacterianas
MX383577B (es) Derivados sustituidos de guanidina.
CL2019000857A1 (es) Compuestos heterocíclicos y su uso para prevenir o tratar las infecciones bacterianas.
EP4286001A3 (en) Benzoylglycine derivatives and methods of making and using same
MX2019006768A (es) Peptidos antimicrobianos.
EA201890412A1 (ru) АНТИБАКТЕРИАЛЬНЫЕ АГЕНТЫ, СОДЕРЖАЩИЕ ПИРАЗИНО[2,3-b][1,4]ОКСАЗИН-3-ОН ИЛИ РОДСТВЕННУЮ КОЛЬЦЕВУЮ СИСТЕМУ
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
WO2018039077A8 (en) Therapeutic compounds
MX379576B (es) Derivados de azetidina